Mixtard 30 (Insulin Human)

Insulin human mimics the action of natural pancreatic insulin. It binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake, inhibit hepatic glucose production, and promote storage of glucose as glycogen, thereby lowering circulating blood glucose concentrations.

The dose of Mixtard 30 is individualized and set by a qualified prescriber based on factors such as the patient’s age, weight, type of diabetes, current glycaemic control, dietary intake, activity level, and concurrent medications. Regular monitoring of blood glucose guides dose adjustments.

The safety of insulin human in pregnancy and lactation is not fully established; it is generally prescribed only when the expected benefit to the mother outweighs potential risks to the fetus or infant. Healthcare providers should evaluate each case carefully and monitor maternal and fetal health closely.

To order Mixtard 30, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain handling) and assists with any required import documentation.

Mixtard 30 is a premixed insulin containing both short‑acting and intermediate‑acting components, offering a simpler injection schedule compared with basal‑bolus regimens that require separate rapid‑acting and long‑acting insulins. While convenient, it provides less flexibility for precise dose titration than basal‑bolus therapy, which may be preferred in patients needing individualized basal and prandial dosing.

Mixtard 30 must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, the vial may be allowed to reach room temperature for a few minutes, but the solution must remain clear and free of particles. Discard any vial that appears discolored or cloudy.

Mixtard 30 is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated with each dose to reduce the risk of lipodystrophy. The exact timing (e.g., before meals) and injection technique are determined by the prescribing clinician based on the patient’s treatment plan.

The most serious risks include severe hypoglycaemia, which can lead to seizures, loss of consciousness or injury, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical assistance if a severe reaction occurs.

Mixtard 30 should not be used by individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycaemia at the time of administration. Caution is advised in patients with severe renal or hepatic impairment, and use during pregnancy or lactation should be limited to situations where benefits outweigh risks.